These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 28937941)

  • 1. The Scheduling of Kratom and Selective Use of Data.
    Griffin OH; Webb ME
    J Psychoactive Drugs; 2018; 50(2):114-120. PubMed ID: 28937941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Notes from the Field: Kratom (Mitragyna speciosa) Exposures Reported to Poison Centers - United States, 2010-2015.
    Anwar M; Law R; Schier J
    MMWR Morb Mortal Wkly Rep; 2016 Jul; 65(29):748-9. PubMed ID: 27466822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The abuse potential of kratom according the 8 factors of the controlled substances act: implications for regulation and research.
    Henningfield JE; Fant RV; Wang DW
    Psychopharmacology (Berl); 2018 Feb; 235(2):573-589. PubMed ID: 29273821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kratom exposures reported to United States poison control centers: 2011-2017.
    Post S; Spiller HA; Chounthirath T; Smith GA
    Clin Toxicol (Phila); 2019 Oct; 57(10):847-854. PubMed ID: 30786220
    [No Abstract]   [Full Text] [Related]  

  • 5. Kratom policy: The challenge of balancing therapeutic potential with public safety.
    Prozialeck WC; Avery BA; Boyer EW; Grundmann O; Henningfield JE; Kruegel AC; McMahon LR; McCurdy CR; Swogger MT; Veltri CA; Singh D
    Int J Drug Policy; 2019 Aug; 70():70-77. PubMed ID: 31103778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Update on the Pharmacology and Legal Status of Kratom.
    Prozialeck WC
    J Am Osteopath Assoc; 2016 Dec; 116(12):802-809. PubMed ID: 27893147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kratom exposures reported to Texas poison centers.
    Forrester MB
    J Addict Dis; 2013; 32(4):396-400. PubMed ID: 24325774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kratom: An Emerging Issue and Need for Regulations in the United States.
    Shah K; Tankersley W; Mekala H
    Prim Care Companion CNS Disord; 2021 Feb; 23(1):. PubMed ID: 34000147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparative analysis of kratom exposure cases in Thailand and the United States from 2010-2017.
    Davidson C; Cao D; King T; Weiss ST; Wongvisavakorn S; Ratprasert N; Trakulsrichai S; Srisuma S
    Am J Drug Alcohol Abuse; 2021 Jan; 47(1):74-83. PubMed ID: 33232183
    [No Abstract]   [Full Text] [Related]  

  • 10. Kratom exposures among older adults reported to U.S. poison centers, 2014-2019.
    Graves JM; Dilley JA; Terpak L; Brooks-Russell A; Whitehill JM; Klein TA; Liebelt E
    J Am Geriatr Soc; 2021 Aug; 69(8):2176-2184. PubMed ID: 34143890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The therapeutic potential of kratom.
    Grundmann O; Brown PN; Henningfield J; Swogger M; Walsh Z
    Addiction; 2018 Oct; 113(10):1951-1953. PubMed ID: 29949213
    [No Abstract]   [Full Text] [Related]  

  • 12. The pharmacology and toxicology of kratom: from traditional herb to drug of abuse.
    Warner ML; Kaufman NC; Grundmann O
    Int J Legal Med; 2016 Jan; 130(1):127-38. PubMed ID: 26511390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kratom: Implications for Health Care Providers.
    Goldin D; Salani D; Mckay M
    J Psychosoc Nurs Ment Health Serv; 2019 Dec; 57(12):15-20. PubMed ID: 31774129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical outcomes after Kratom exposures: A poison center case series.
    Cumpston KL; Carter M; Wills BK
    Am J Emerg Med; 2018 Jan; 36(1):166-168. PubMed ID: 28751041
    [No Abstract]   [Full Text] [Related]  

  • 15. Kratom abuse in Ramathibodi Poison Center, Thailand: a five-year experience.
    Trakulsrichai S; Tongpo A; Sriapha C; Wongvisawakorn S; Rittilert P; Kaojarern S; Wananukul W
    J Psychoactive Drugs; 2013; 45(5):404-8. PubMed ID: 24592666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kratom (Mitragyna speciosa) dependence, withdrawal symptoms and craving in regular users.
    Singh D; Müller CP; Vicknasingam BK
    Drug Alcohol Depend; 2014 Jun; 139():132-7. PubMed ID: 24698080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Do You Get What You Paid For? An Examination of Products Advertised as Kratom.
    Griffin OH; Daniels JA; Gardner EA
    J Psychoactive Drugs; 2016; 48(5):330-335. PubMed ID: 27669103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Schedules of controlled substances: temporary placement of three synthetic cannabinoids into Schedule I. Final order.
    Drug Enforcement Administration, Department of Justice
    Fed Regist; 2013 May; 78(95):28735-9. PubMed ID: 23678676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DEA reschedules hydrocodone, makes changes to controlled substance disposal.
    Traynor K
    Am J Health Syst Pharm; 2014 Nov; 71(22):1916-8. PubMed ID: 25349231
    [No Abstract]   [Full Text] [Related]  

  • 20. Establishment of drug codes for 26 substances. Final rule.
    Drug Enforcement Administration (DEA), Department of Justice
    Fed Regist; 2013 Jan; 78(3):664-6. PubMed ID: 23289157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.